Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $17.28 USD
Change Today +0.26 / 1.53%
Volume 8.4K
PRTO On Other Exchanges
As of 5:20 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

proteon therapeutics inc (PRTO) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/17/15 - $20.00
52 Week Low
12/8/14 - $8.57
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

proteon therapeutics inc (PRTO) Related Businessweek News

No Related Businessweek News Found

proteon therapeutics inc (PRTO) Details

Proteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in a Phase III clinical trials for the treatment of radiocephalic arteriovenous fistula to enable hemodialysis; has completed a Phase I/II clinical trials for the treatment of patients undergoing surgical placement of an arteriovenous graft; and is in a Phase I clinical trials for the treatment of symptomatic peripheral artery diseases. The company was founded in 2001 and is headquartered in Waltham, Massachusetts.

11 Employees
Last Reported Date: 03/20/15
Founded in 2001

proteon therapeutics inc (PRTO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $408.2K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $289.4K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $369.1K
Vice President of Corporate Development
Total Annual Compensation: $242.4K
Compensation as of Fiscal Year 2014.

proteon therapeutics inc (PRTO) Key Developments

Proteon Therapeutics Inc. Appoints Scott Canute to its Board of Directors

Proteon Therapeutics Inc. announced the appointment of Scott Canute to its board of directors. Mr. Canute has more than 30 years of experience in the life science industry, with particular expertise in manufacturing and operations. Mr. Canute is the former President of Global Manufacturing Operations at Eli Lilly and Company and former President of Global Manufacturing and Corporate Operations at Genzyme Corporation.

Proteon Therapeutics Inc(NasdaqGM:PRTO) added to Russell 2000 Index

Proteon Therapeutics Inc will be added to Russell 2000 Index

Proteon Therapeutics Inc(NasdaqGM:PRTO) added to Russell 3000 Index

Proteon Therapeutics Inc will be added to the Russell 3000 Index.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PRTO:US $17.28 USD +0.26

PRTO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PRTO.
View Industry Companies

Industry Analysis


Industry Average

Valuation PRTO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 95.0x
Price/Book 3.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 68.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROTEON THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at